-
Ferring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million
in PRESS RELEASE 2020 onFerring Pharmaceuticals announced the successful launch of its inaugural Swiss Franc Bond offering for a benchmark amount of CHF 270 million. This inaugural senior unsecured bond transaction issued by Ferring Holding SA has a fixed coupon rate of 1.05% per annum.
0 -
“Standing together against injustice” – a message from Per Falk, President and Chief Science Officer at Ferring
in Uncategorized on“Standing together against injustice” – a message from Per Falk, President and…
-
Ferring and Igenomix collaborate to advance care in reproductive medicine and maternal health
in PRESS RELEASE 2020 onFerring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
-
Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births
in Uncategorized onFerring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section. Every year, 14 million women experience excessive bleeding after birth, also known as postpartum haemorrhage…
-
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
in Uncategorized onToday, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its clinical…
-
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
in Uncategorized onRebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy…
-
Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years
in Uncategorized onFerring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW)…
-
Ferring 70th Anniversary
in TIMELINES onLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
-
FerGene Appoints David Meek Chief Executive Officer
in Uncategorized onFerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, today announced the appointment of David Meek as President and Chief Executive Officer …
-
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec
in Uncategorized onFerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec …
Author archive for pulse
Articles by: pulse